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405 citations. Two reviewers independently examined each citation and abstract. We
conducted three levels of review resulting in 94 papers for full review. Data were
analyzed using qualitative and quantitative methods, including a meta-analysis using 
a random effects model (REM) and Mantel-Haenszel (MH) summary estimate.
RESULTS: The most common research design involved randomized controlled trials
(RCTs) (60/94, 64%). Seventy-two (77%) studies involved interventions that sought
to directly improve medication compliance, 12 (13%) had to do with interventions to
improve compliance through a multidisciplinary process, 5 (5%) involved interven-
tions to indirectly improve compliance through changing physician practice, and 5 
(5%) were other types. Thirteen studies (14%) involved the use of a theoretical 
framework to guide the research. A meta-analysis was conducted of RCTs of educa-
tional interventions, (N  6). The REM showed a trend toward statistical signiﬁ cance
with a risk ratio of 0.83 for non-compliance (95% CI: 0.68 1.00, p  0.05). The
MH summary estimate was statistically signiﬁ cant with a risk ratio of 0.83 for non-
compliance (95% CI: 0.75–0.92, p  0.00), favoring patients who received educational 
interventions to improve compliance. However, the X2 test for heterogeneity was sig-
niﬁ cant; p  0.020 and p  0.016 respectively. CONCLUSIONS: Our analysis indi-
cated that most interventions focused on directly improving medication compliance. 
The meta-analysis illustrated educational strategies provide a signiﬁ cant beneﬁ t in 
reducing non-compliance in patients using antihypertensives. The small sample size 
may have contributed to the observed heterogeneity and require additional investiga-
tion. Our ﬁ ndings have implications for designing future research and implementing 
educational interventions.
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HEALTH CARE RESOURCE UTILIZATION AMONG PATIENTS TREATED
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THERAPIES AMONG PATIENTS WITH DYSLIPIDEMIA IN A MANAGED 
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OBJECTIVES: Evaluate the impact of medication adherence on total health care
resource utilization (THR) among dyslipidemia patients initiating ﬁ xed dose combina-
tion (FDC) therapy versus multi-pill combination (MPC) therapies in a managed care
population. METHODS: Using claims data from the HealthCore Integrated Research 
Database, study patients q18 years were identiﬁ ed as newly-initiating on FDC 
[Advicor: niacin extended release (NER)  lovastatin] or MPC’s [simvastatin  NER
(NER/S), lovastatin  NER (NER/L)] between January 1, 2000-June 30, 2006 [index 
date], with a minimum 6 months pre- and 12 months post-index health plan eligibility. 
Adherence was measured using medication possession ratio (MPR). Multivariate 
negative binomial regression was used to estimate association between study cohorts 
and one-year post-index cardiovascular disease (CVD)-related THR (sum of emer-
gency room, inpatient, and outpatient visits) after controlling for differences in base-
line age, gender, THR, Deyo-Charlson comorbidity index (DCI) score, number of 
non-dyslipidemia medications, and post-index adherence. RESULTS: Among study 
patients [8988 patients (6638 FDC; 1687 NER/S; 663 NER/L)], those initiating FDC 
therapy were signiﬁ cantly younger [mean (SD) ages of 51.9 (10.5) vs. 56.0 (9.8) years,
p  0.0001], comprised of fewer males (73.0% vs. 81.5%; p  0.0001), and had sig-
niﬁ cantly lower baseline DCI scores (0.43 o 0.88 vs. 0.59 o 1.06; p  0.0001) versus
MPC patients. During one-year follow-up, average MPR was higher among FDC
patients versus both NER/S and NER/L patients (0.54 o 0.35 vs. 0.50 o 0.35 and 0.47
o 0.34, respectively; p  0.01). Controlling for post-index adherence, multivariate
regression demonstrated that FDC patients had an 18% decrease in annual CVD-
related THR versus MPC patients [IRR: 0.819, 95% CI: 0.761–0.882); p  0.0001]. 
CONCLUSIONS: FDC-initiated patients showed improved medication adherence and
reduced CVD-related THR versus MPC-initiated patients in this managed care popula-
tion. Further studies on clinical and economic impact of improved adherence to FDC
dyslipidemia therapy are warranted.
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CHARACTERISTICS ON PATIENT PERSISTENCE IN CHRONIC MARKETS
Henderson SC1, Denarie MF2, Yuan Y1
1IMS Health, Blue Bell, PA, USA, 2IMS Health, Plymouth Meeting, PA, USA
OBJECTIVES: Although patient ﬁ nances are widely studied as predictors of adherence,
claims databases rarely include variables other than copay and insurance coverage.
Linking personal income, level of education, and ethnicity to prescription data can
enhance analyses of socioeconomic factors and adherence. We compared persistence 
in chronic markets – statins and oral antidiabetics (OADs) – by income, education, 
and ethnicity in linked administrative databases. METHODS: Using IMS’ LifeLink 
longitudinal prescription database (LRx), linked to commercial socio-economic data, 
we selected 143,370 patients initiating statins and 57,079 patients initiating OADs 
after a minimum 12 month clean period. LRx captures 62% of prescription claims
contributed by retail pharmacies in the US. Cox proportional hazards models compared
persistence by income, education, ethnicity, age, and method of payment. RESULTS:
Mean days of statin persistence was higher for patients with household income 
$75K/yr (149 days) than for patients with $40–75,000K/year household income
(144 days) (p  0.001). Patients with very low income ($K/yr) were more frequently 
on Medicaid or over age 65; these very low income patients had higher persistence
(150 days) than patients with income of $15$40,000/year (144 days) (p  0.005). 
Persistence also increased with level of education (graduate school  154 days vs. high 
school  147 days, p  0.001) and differed by ethnicity (Caucasian  150 days, Hispanic 
 127 days, African American  124 days; p  0.001). Similar trends were observed 
with OADs. CONCLUSIONS: Patients with higher household income demonstrate 
slightly improved persistence, while patients with very low income, but subsidized 
pharmacy beneﬁ ts, also have higher than average persistence. Differences in persistence 
also are found with higher levels of education and across ethnic groups.
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FRACTION OF NURSING HOME ADMISSION AND INCREMENTAL COST
ATTRIBUTABLE TO NON ADHERENCE TO ANTI HYPERTENSIVE 
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OBJECTIVES: We estimated the relationship between nursing home admission and 
non-adherence to anti-hypertensive medications. We calculated the incremental 
proportion of nursing home admission that was due to non-adherence, and the
annual incremental cost of the proportion of nursing home admission due to non-
adherence. METHODS: We calculated adherence scores in a cohort of 225,624 sub-
jects with hypertension from the MarketScan database. We used a generalized linear 
model with a binomial distribution and a log link to estimate adjusted relative risks
of nursing home admission. We calculated the fraction of nursing home admission
attributable to non-adherence. RESULTS: We showed that non-adherence to anti-
hypertensive medications increases the risk of nursing home admission. Among non-
adherent subjects, 10.8% were admitted to nursing homes. In the general population
of community-dwelling elderly subjects, 1.9% of nursing home admissions were 
attributable to non-adherence to anti-hypertensive medication. Extending these results
to the United States elderly (age q 65) population with hypertension, we found that 
annually 28,372 subjects were admitted to nursing homes in 2002 because of non-
adherence to anti-hypertensive medications. In 2002, the cost of nursing home admis-
sion due to non-adherence was estimated to be $1.7 billion. CONCLUSIONS:
Anti-hypertensive medication non-adherence was a risk factor for elderly transitioning
to long-term care facilities. Since non-adherence may be viewed as a proxy for lack 
of social support, our results show the potential beneﬁ ts related to interventions that
could provide social support to elderly patients, such as assistance with medication 
administration.
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OBJECTIVES: Poor adherence to anti-hypertensives severely compromises the effec-
tiveness of treatment. The aim of this study was to measure adherence to antihyper-
tensive therapy and to determine the factors that are associated with poor adherence
in a sample of hypertensive patients in Nsukka, a semi urban town located in South-
Eastern Nigeria. METHODS: A cross sectional, household survey was conducted in
Nsukka. Adherence to antihypertensive medications was assessed on participants that
were hypertensive. Patient self-reports about the number of pills taken over a pre-
scribed period were used to estimate adherence as a percentage. In addition, Morisky 
Medication Adherence Scale (MMAS) was used in order to increase the strength and 
consistency of patient’s self-report on adherence. RESULTS: A total of 756 partici-
pants were screened for hypertension. Forty-seven persons were hypertensive. Mean 
adherence to hypertension medication was 70.7% o 37.9%. Mean adherence score 
was correlated to MMAS score (r  0.401, p  0.05). Educational status, making 
medications a habit, and experience of side effects were independently correlated to
adherence. Multiple linear regression showed that for every increase in educational 
status, adherence increased by 12.1%. Also making medication a habit increased 
adherence by 35.09%. However, experience of side-effect decreased adherence by
20.1%. CONCLUSIONS: These factors identiﬁ ed as correlates of adherence to anti-
hypertensives in the study population could be used to design interventions to improve 
adherence to hypertension medications in Nigeria.
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OBJECTIVES: A common side effect of niacin therapy is ﬂ ushing characterized by 
warmth, redness, itching, and/or tingling. The FAST was developed to assess ﬂ ushing 
symptoms and clinical impact on patients. This study evaluated the psychometrics and
minimal important difference (MID) of the FAST. METHODS: A randomized, double-
blind, parallel group, multicenter, placebo (PBO)-controlled prospective 6-week study 
evaluated the FAST. 269 patients with dyslipidemia were randomized (1:1:1) to niacin 
extended-release (NER)/acetylsalicylic acid (ASA), NER/ASA PBO, or PBO/PBO. 
Patients completed the FAST electronic diary daily. RESULTS: FAST test-retest reli-
ability during the ﬁ rst 2 weeks among stable subjects was demonstrated for mean
overall ﬂ ushing severity using patient/physician-rated overall treatment effect (OTE) 
ratings (intraclass correlation coefﬁ cients of 0.75 and 0.76). Over the 6 week treatment
